Capecitabine (XELODA) With Or Without Lapatinib(GW572016)For Women With Refractory Advanced or Metastatic Breast Cancer - Related Studies

Capecitabine (XELODA) With Or Without Lapatinib(GW572016)For Women With Refractory Advanced or Metastatic Breast Cancer

This study is ongoing, but not recruiting participants.

Study NCT00078572. Last updated on November 26, 2008. Information provided by GlaxoSmithKline

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Breast Cancer

2	Additional conditions recognized in this trial
		Breast Neoplasms

3	More general conditions related to this trial
		Breast Diseases
		Neoplasms
		Neoplasms by Site
		Skin Diseases

4	Interventions listed in this trial
		capecitabine
		lapatinib (GW572016)

5	Additional drug interventions recognized in this trial
		Lapatinib

6	More general drug interventions related to this trial
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protein Kinase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		GlaxoSmithKline